“Zosano’s investors are an experienced team from: New Enterprise Associates (NEA), Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments.”
“Our transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability.”
“Our transdermal system has been clinically tested in over 300 patients with four different peptides and a vaccine.”
“Our system can deliver therapeutic peptides, proteins, small molecules, biopharmaceuticals and vaccines.”
“Our Regulatory strategy leverages existing products safety and efficacy data, like PTH, which could improve our productivity.”
“In addition to convenience and stability benefits, our system provided rapid and efficient drug delivery beyond existing injectable products.”
“Zosano is positioned to succeed because of our strong financial backing, substantive IP positions, exciting technology and strong Team.”
“Our innovative sterile manufacturing process is state-of-the-art and is a distinct competitive advantage for Zosano.”
“The innovative product provides good stability, well beyond existing injectable products, which could provide storage and distribution benefits customers.”
Our Vision:
Creating better products utilizing innovative drug delivery technology.
Our Mission: Working on our own and with partners to establish Zosano Pharma as the leading drug delivery innovator of peptides, proteins, small molecules and vaccines.
Our Values: